Cencora to Manage U.S. Distribution for Kite CAR T-Cell Therapies Yescarta and Tecartus

Cencora and Kite have entered into a new agreement to manage the distribution of the CAR T-cell therapies Yescarta and Tecartus across the United States. This partnership aims to streamline administrative processes for authorized treatment centers and increase the availability of these specialized cell and gene therapies for patients.

Under the terms of the agreement, Cencora will oversee the logistics and supply chain operations for both treatments. By centralizing these distribution tasks, the companies intend to reduce the administrative workload currently placed on healthcare providers. This shift in the commercialization model seeks to shorten the time required for patients to receive therapy by simplifying the coordination between the manufacturer and the clinical sites authorized to administer these treatments.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI